The biotechnology industry stands at a critical juncture as rising development costs and increasing regulatory complexity challenge traditional business models, according to veteran executive Jeremy Levin, former CEO of Ovid Therapeutics and Teva Pharmaceutical Industries. Speaking on STAT’s “The Readout LOUD” podcast, Levin outlined how companies must fundamentally rethink their approach to drug development and commercialization.
Biotech Funding Challenges Intensify
Venture capital investment in biotech companies, 2019-2024, billions USD
in 2021
investment
from peak
Source: PitchBook Data, 2024 | Georgian Medical Journal News
Industry Transformation Requires New Strategic Thinking
Levin, who has led multiple pharmaceutical and biotech companies over three decades, emphasized that the industry must move beyond traditional venture capital-funded models. The current environment demands more sophisticated partnerships between academia, industry, and government agencies to share both risks and rewards of drug development.
The challenges are particularly acute for smaller biotech companies, which have historically relied on venture funding to advance early-stage programs. According to National Institutes of Health data, the average time from discovery to market approval now exceeds 15 years, creating prolonged cash burn periods that strain investor patience.
“Companies need to fundamentally rethink how they approach innovation and risk management,” Levin noted in his discussion, highlighting the need for more efficient clinical trial designs and regulatory pathways. This strategic shift comes as regulatory agencies worldwide are simultaneously pushing for faster approvals while maintaining safety standards.
Regulatory Complexity Drives Strategic Realignment
The regulatory landscape has become increasingly complex, with different approval pathways across global markets creating additional development costs. FDA breakthrough therapy designations and accelerated approval pathways offer some relief, but companies must navigate varying requirements across Europe, Asia, and other key markets.
Levin’s perspective reflects broader industry concerns about sustainable business models in an environment where traditional metrics of success are being challenged. The emphasis on real-world evidence and post-market surveillance adds layers of complexity that require new operational capabilities.
For patients and healthcare systems, these industry changes have direct implications for drug access and pricing. Patient advocacy groups are increasingly vocal about balancing innovation incentives with affordability concerns, creating additional pressure on biotech business models.
Technology Integration Reshapes Development Paradigms
Artificial intelligence and machine learning are increasingly central to drug discovery and development processes, potentially reducing both time and costs. However, the integration of these technologies requires significant upfront investment and new expertise that many smaller companies struggle to acquire.
Platform technologies that can address multiple diseases or therapeutic areas are becoming more attractive to investors seeking diversified risk profiles. This trend toward platform approaches represents a shift from the traditional “one drug, one indication” model that has dominated biotech for decades.
The discussion with Levin highlighted how successful companies are those that can adapt their strategies to leverage both technological advances and evolving regulatory frameworks. World Health Organization initiatives around essential medicines also influence how companies prioritize their development portfolios.
The biotechnology industry must fundamentally rethink traditional venture capital-funded models as development costs reach $2.6 billion per new drug and regulatory complexity increases across global markets.
— Jeremy Levin, Former CEO of Ovid Therapeutics (STAT “The Readout LOUD” Podcast, 2026)
Key takeaways
- Biotech companies face a strategic inflection point driven by rising development costs averaging $2.6 billion per new drug
- Venture capital funding has declined 37% from 2021 peaks, forcing companies to explore alternative financing models
- Successful adaptation requires integration of new technologies, efficient clinical trial designs, and sophisticated risk-sharing partnerships
Frequently asked questions
What is causing the biotech industry’s strategic challenges?
Rising drug development costs, averaging $2.6 billion per new drug according to Tufts Center data, combined with declining venture capital investment and increasing regulatory complexity across global markets. The average development timeline now exceeds 15 years, creating prolonged cash burn periods.
How are companies adapting to these challenges?
Leading companies are moving beyond traditional VC-funded models toward sophisticated partnerships between academia, industry, and government agencies. They’re also leveraging AI and machine learning technologies and developing platform approaches that can address multiple therapeutic areas.
What does this mean for patients and drug access?
The industry transformation could lead to more efficient drug development processes and potentially faster approvals through breakthrough therapy designations. However, balancing innovation incentives with drug affordability remains a key challenge as companies seek sustainable business models.
The biotechnology sector’s evolution will likely determine not only which companies survive the current challenging environment, but also how quickly breakthrough therapies reach patients in need. As regulatory agencies worldwide balance safety requirements with approval speed, and as new technologies reshape discovery processes, the industry’s ability to adapt will ultimately define its contribution to global health outcomes. The strategic decisions made today by biotech leaders will shape the therapeutic landscape for the next decade.
Source: Biotech exec Jeremy Levin on the industry’s strategic turning point
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
